Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Price:
12.87 USD
-5.44%
Updated:
May 10, 2024
Y-mAbs Therapeutics Inc
Research & Development
|
Y-mAbs Therapeutics Inc
Research & Development Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
|
Research & Development
-$50.9m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$6.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$4.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-17%
|
See Also
What is Y-mAbs Therapeutics Inc's Research & Development?
Research & Development
-50.9m
USD
-50.9m
USD
Based on the financial report for Dec 31, 2023, Y-mAbs Therapeutics Inc's Research & Development amounts to -50.9m USD.
What is Y-mAbs Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-8%
-8%
Over the last year, the Research & Development growth was 44%. The average annual Research & Development growth rates for Y-mAbs Therapeutics Inc have been 18% over the past three years , -8% over the past five years .
You don't have any saved screeners yet
